Literature DB >> 10907734

Piracetam reverses hippocampal membrane alterations in Alzheimer's disease.

G P Eckert1, N J Cairns, W E Müller.   

Abstract

The in vitro effects of piracetam treatment on the fluidity of membranes from the hippocampus of Alzheimer's Disease patients (AD) and non-demented controls were studied. Hippocampal membranes of AD patients showed a significant lower hydrocarbon core fluidity compared with membranes from elderly non-demented controls. Preincubation with piracetam enhanced the hydrocarbon core fluidity of hippocampal membranes from AD-patients as well as elderly controls in a concentration depending fashion, although the effect was more pronounced for the AD membranes. In the presence of piracetam, the difference of the membrane fluidity between AD and control membranes was not longer apparent.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10907734     DOI： 10.1007/s007020050196

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  9 in total

1.  Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing.

Authors:  Xiaoguang Yang; Wenwen Sheng; Grace Y Sun; James C-M Lee
Journal:  Neurochem Int       Date:  2010-12-22       Impact factor: 3.921

2.  Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine.

Authors:  Omar M E Abdel-Salam; Yasser A Khadrawy; Neveen A Salem; Amany A Sleem
Journal:  Neurochem Res       Date:  2011-03-30       Impact factor: 3.996

3.  Piracetam improves mitochondrial dysfunction following oxidative stress.

Authors:  Uta Keil; Isabel Scherping; Susanne Hauptmann; Katin Schuessel; Anne Eckert; Walter E Müller
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Authors:  Gunter P Eckert; Kathrin Renner; Schamim H Eckert; Janett Eckmann; Stephanie Hagl; Reham M Abdel-Kader; Christopher Kurz; Kristina Leuner; Walter E Muller
Journal:  Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.590

5.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

6.  Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5'-nucleotidase and adenosine deaminase activities.

Authors:  Patricia C Marisco; Fabiano B Carvalho; Michelle M Rosa; Bruna A Girardi; Jessié M Gutierres; Jeandre A S Jaques; Ana P S Salla; Víctor C Pimentel; Maria Rosa C Schetinger; Daniela B R Leal; Carlos F Mello; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-05-16       Impact factor: 3.996

Review 7.  Mechanisms associated with the dysregulation of mitochondrial function due to lead exposure and possible implications on the development of Alzheimer's disease.

Authors:  Lakshmi Jaya Madhuri Bandaru; Neelima Ayyalasomayajula; Lokesh Murumulla; Suresh Challa
Journal:  Biometals       Date:  2022-01-20       Impact factor: 2.949

8.  Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function.

Authors:  Carola Stockburger; Davide Miano; Thea Pallas; Kristina Friedland; Walter E Müller
Journal:  Neural Plast       Date:  2016-09-26       Impact factor: 3.599

9.  The synthesis and evaluation of novel hydroxyl substituted chalcone analogs with in vitro anti-free radicals pharmacological activity and in vivo anti-oxidation activity in a free radical-injury Alzheimer's model.

Authors:  Ying Pan; Yicun Chen; Qingnan Li; Xiaoyu Yu; Jinzhi Wang; Jinhong Zheng
Journal:  Molecules       Date:  2013-01-28       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.